Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Semaglutide is making waves as the powerhouse ingredient in Ozempic and ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...

Amanda Bynes shared she bought a grill instead of tooth gems due to having veneers, showcasing her sparkling new jewelry on ...